"We expect that this collaboration will be a critical advantage for Aastrom as we move our cardiovascular programs into the final stages of clinical development," said Aastrom CEO Tim Mayleben in prepared remarks.
Tim Mayleben had a front-row seat as a board member to the shaky period two years ago when stem cell company Aastrom Biosciences was clinging to survival. Now, he’s in the driver’s seat as things are looking up for the publicly traded biotech firm. In 2012, Aastrom (Nasdaq: ASTM) could launch its first product–a treatment […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.